172 related articles for article (PubMed ID: 9474803)
21. Combination of cytokine-induced killer and dendritic cells pulsed with antigenic α-1,3-galactosyl epitope-enhanced lymphoma cell membrane for effective B-cell lymphoma immunotherapy.
Qiu Y; Yun MM; Dong X; Xu M; Zhao R; Han X; Zhou E; Yun F; Su W; Liu C; Zhao H; Tong X; Gao J; Ouyang X; Yun S
Cytotherapy; 2016 Jan; 18(1):91-8. PubMed ID: 26549382
[TBL] [Abstract][Full Text] [Related]
22. Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells.
Manches O; Plumas J; Lui G; Chaperot L; Molens JP; Sotto JJ; Bensa JC; Galili U
Haematologica; 2005 May; 90(5):625-34. PubMed ID: 15921377
[TBL] [Abstract][Full Text] [Related]
23. Treatment of B-cell lymphoma using peptides. A novel concept.
Lam KS
West J Med; 1993 May; 158(5):475-9. PubMed ID: 8342262
[TBL] [Abstract][Full Text] [Related]
24. In vitro priming of myeloma antigen-specific allogeneic donor T cells with idiotype pulsed dendritic cells.
Kim SB; Baskar S; Kwak LW
Leuk Lymphoma; 2003 Jul; 44(7):1201-8. PubMed ID: 12916873
[TBL] [Abstract][Full Text] [Related]
25. [Induction of T cell responses against autologous ovarian cancer by anti-idiotype minibody-pulsed dendritic cells].
Yang WL; Cui H; Feng J; Chang XH; Fu TY; Ye X; Zhang H; Li XP; Wen HW; Feng LM; Tong CR
Ai Zheng; 2004 Dec; 23(12):1639-45. PubMed ID: 15601552
[TBL] [Abstract][Full Text] [Related]
26. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma.
Davis TA; Hsu FJ; Caspar CB; van Beckhoven A; Czerwinsk DK; Liles TM; Taidi B; Benike CJ; Engleman EG; Levy R
Biol Blood Marrow Transplant; 2001; 7(9):517-22. PubMed ID: 11669219
[TBL] [Abstract][Full Text] [Related]
27. Generation of primary peptide-specific CD8+ cytotoxic T-lymphocytes in vitro using allogeneic dendritic cells.
Peshwa MV; Benike C; Dupuis M; Kundu SK; Engleman EG; Merigan TC; van Schooten WC
Cell Transplant; 1998; 7(1):1-9. PubMed ID: 9489758
[TBL] [Abstract][Full Text] [Related]
28. Dendritic cell as therapeutic vaccines against tumors and its role in therapy for hepatocellular carcinoma.
Sun K; Wang L; Zhang Y
Cell Mol Immunol; 2006 Jun; 3(3):197-203. PubMed ID: 16893500
[TBL] [Abstract][Full Text] [Related]
29. Dendritic cell biology and its role in tumor immunotherapy.
Wang Y; Xiang Y; Xin VW; Wang XW; Peng XC; Liu XQ; Wang D; Li N; Cheng JT; Lyv YN; Cui SZ; Ma Z; Zhang Q; Xin HW
J Hematol Oncol; 2020 Aug; 13(1):107. PubMed ID: 32746880
[TBL] [Abstract][Full Text] [Related]
30. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo.
Flamand V; Sornasse T; Thielemans K; Demanet C; Bakkus M; Bazin H; Tielemans F; Leo O; Urbain J; Moser M
Eur J Immunol; 1994 Mar; 24(3):605-10. PubMed ID: 8125131
[TBL] [Abstract][Full Text] [Related]
31. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma.
Singh A; Qin H; Fernandez I; Wei J; Lin J; Kwak LW; Roy K
J Control Release; 2011 Oct; 155(2):184-92. PubMed ID: 21708196
[TBL] [Abstract][Full Text] [Related]
32. Vaccination as immunotherapy for B cell lymphoma.
Schultze JL
Hematol Oncol; 1997 Aug; 15(3):129-39. PubMed ID: 9600112
[TBL] [Abstract][Full Text] [Related]
33. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects.
Titzer S; Christensen O; Manzke O; Tesch H; Wolf J; Emmerich B; Carsten C; Diehl V; Bohlen H
Br J Haematol; 2000 Mar; 108(4):805-16. PubMed ID: 10792287
[TBL] [Abstract][Full Text] [Related]
34. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
35. From dendritic cells to tumour vaccines.
Hamblin TJ
Lancet; 1996 Mar; 347(9003):705-6. PubMed ID: 8601996
[No Abstract] [Full Text] [Related]
36. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
37. Breaking tolerance to tumors with dendritic cell-based immunotherapy.
Mende I; Engleman EG
Ann N Y Acad Sci; 2005 Nov; 1058():96-104. PubMed ID: 16394129
[TBL] [Abstract][Full Text] [Related]
38. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.
Kwak LW; Campbell M; Levy R
Cancer Detect Prev; 1991; 15(4):323-5. PubMed ID: 1794139
[TBL] [Abstract][Full Text] [Related]
39. Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo.
Franki SN; Steward KK; Betting DJ; Kafi K; Yamada RE; Timmerman JM
Blood; 2008 Feb; 111(3):1504-11. PubMed ID: 17993615
[TBL] [Abstract][Full Text] [Related]
40. The role of tumor necrosis factor alpha in modulating the quantity of peripheral blood-derived, cytokine-driven human dendritic cells and its role in enhancing the quality of dendritic cell function in presenting soluble antigens to CD4+ T cells in vitro.
Chen B; Shi Y; Smith JD; Choi D; Geiger JD; Mulé JJ
Blood; 1998 Jun; 91(12):4652-61. PubMed ID: 9616162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]